Day One Biopharma Expands to ADCs with $55M Drug Acquisition

Day One Biopharmaceuticals Expands Pipeline with Promising New Cancer Drug DAY301

Day One Biopharmaceuticals, a company now in its commercial-stage journey after securing FDA approval for its first drug two months ago, is strengthening its product line. They've struck a deal that grants them rights to a novel cancer drug, ready for its first human trial.